Determining ocriplasmin success

Article

A new agent aimed at treating symptomatic vitreomacular adhesion may lead to variable outcomes based on several pre-treatment patient characteristics.

Before the 2012 approval of ocriplasmin (Jetrea, Alcon, Fort Worth, Texas, USA), the primary treatments for symptomatic VMA were either observation or vitrectomy with separation of the posterior hyaloid.

Secondary endpoints included: the development of a total posterior vitreous detachment at day 28; nonsurgical closure of full thickness macular hole; visual acuity changes of more than 2 or 3 lines of visual acuity; need for vitrectomy; and improvement in the VFQ-25 assessment.

MIVI-006 enrolled 464 patients, MIVI-007 enrolled 188 patients.

"This was a large cohort study - 652 eyes were treated with a single injection," Dr Hassan said.

Overall, 26.5% of those treated with ocriplasmin had complete VMA resolution at day 28, compared with only 10.1% of those in the sham arm.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Related Content
© 2025 MJH Life Sciences

All rights reserved.